Anti-VEGF injections may be linked to increased risk of cataracts
anti-VEGF

Anti-VEGF injections may be linked to increased risk of cataracts

Several eye conditions are treated using anti-VEGF injections including retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.
Eylea HD receives approval for dosing interval extension
diabetic macular edema

Eylea HD receives approval for dosing interval extension

This updated dosing schedule means that wet AMD and DME patients can now have their treatment plans tailored to their individual needs.
Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Axpaxli

Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug

Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.  
Eydenzelt receives FDA approval for four retinal diseases
diabetic macular edema

Eydenzelt receives FDA approval for four retinal diseases

Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following reetinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Cancer drug may also be a possible treatment for age-related macular degeneration
intravitreal injections

Cancer drug may also be a possible treatment for age-related macular degeneration

Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.